Zenas provides obexelimab trial updates: Ph3 INDIGO topline end-2025, Ph2 data 2025-2026

Zenas BioPharma, Inc.

Phase 3 INDIGO trial in IgG4-RD fully enrolled (over 190 patients); topline results expected year-end 2025.
Phase 2 MoonStone trial in RMS enrolling; 12-week primary endpoint data expected Q3:2025.
Phase 2 SunStone trial in SLE enrolling; 24-week primary endpoint data expected 1H:2026.
Preliminary interim data from Cohort 1 of Phase 2 SApHiAre trial in wAIHA provided.
Company states capitalized for clinical data readouts into Q4:2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.